{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"retatrutide","verification":{"valid":true,"entries":24,"head":"1ab5e0df5e49b2da3698bbc16b7c9ea5ae2f46b47ea53294e5c4acf46c88b54d"},"count":24,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"The primary endpoint was the change in HbA1c concentration from baseline to week 40.","summary":"TRANSCEND-T2D-1, Lancet 2026: the first published phase 3 trial of retatrutide — double-blind and randomised, in people with type 2 diabetes not controlled by diet and exercise. Baseline mean HbA1c 7.9%, mean BMI 35.8.","author":"Bajaj HS, Welch M et al.","publisher":"Lancet (London, England)","date":"2026","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","tag":"Phase 3 trial","prev":"genesis","hash":"39e270374cddb740a5f1805210a916616aeef86019754eb746b0a40df8128677"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40728138/","title":"Efficacy and safety of retatrutide for the treatment of obesity","quote":"This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data.","summary":"2025 systematic review on retatrutide safety/efficacy for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"39e270374cddb740a5f1805210a916616aeef86019754eb746b0a40df8128677","hash":"66cb586a5c30653d670a0baf7f53c9c248e780f0832a0676815ac2562338b2be"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes.","summary":"2025 meta-analysis showing retatrutide superior to placebo for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"66cb586a5c30653d670a0baf7f53c9c248e780f0832a0676815ac2562338b2be","hash":"f80e4f94a8b49e16ebf8fdd80e5ad5711cc77649e284d560a66d7b922e334297"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"2025 meta-analysis on retatrutide for obesity treatment.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"f80e4f94a8b49e16ebf8fdd80e5ad5711cc77649e284d560a66d7b922e334297","hash":"847a5721780ed669c07ef7c7bbe403157a66903703893c8aacae277967a4e179"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile.","summary":"2025 review on retatrutide mechanisms, efficacy, and safety.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"847a5721780ed669c07ef7c7bbe403157a66903703893c8aacae277967a4e179","hash":"767010d787ad1410724e3f72a0db6f9267b03c9b1a97cb39ee618a031a66c722"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"2025 phase 2 substudy on retatrutide effects on body composition in T2D.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"767010d787ad1410724e3f72a0db6f9267b03c9b1a97cb39ee618a031a66c722","hash":"f9dec1ff1843db8b4db3e1aeda00a2c5c534dedc4230a3c9d89251bb17a26f24"},{"id":"s7","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease.","summary":"Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"unverified","prev":"f9dec1ff1843db8b4db3e1aeda00a2c5c534dedc4230a3c9d89251bb17a26f24","hash":"894fa5a96c21023b1d64039a3626257d6ba00a6a0923708758b65bb5e9ed553b"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity-related disease states.","summary":"Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:46.247Z","link_status":"ok","quote_status":"verified","prev":"894fa5a96c21023b1d64039a3626257d6ba00a6a0923708758b65bb5e9ed553b","hash":"eb3e21dd33e63e06263cffd93dfdb3653fa6dbd6cca89117745af2da2bfcc884"},{"id":"s9","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:46.247Z","link_status":"ok","quote_status":"unverified","prev":"eb3e21dd33e63e06263cffd93dfdb3653fa6dbd6cca89117745af2da2bfcc884","hash":"ebbac8c3296c337e13dd663e33d17d9b6ffe9bb434c004cb60fe470e49054ae3"},{"id":"s10","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:46.247Z","link_status":"ok","quote_status":"unverified","prev":"ebbac8c3296c337e13dd663e33d17d9b6ffe9bb434c004cb60fe470e49054ae3","hash":"a767fd2c0ecd15f1406073dc1a969b13a3237c971f378da42aad18e8bc7fcb0c"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41997446/","external_id":"41997446","pmid":"41997446","title":"GIPR:GCGR co-agonism restores normal weight in obese rodents","quote":"Retatrutide a balanced GLP-1R:GIPR:GCGR triagonist normalized body weight in obese GLP-1R KO mice.","summary":"Molecular Metabolism 2026: obesity was reversed in mice with no working GLP-1 receptor at all, isolating what the GIP and glucagon arms contribute. A mechanistic result, not a clinical one.","author":"Perez-Tilve D, Zhang F et al.","publisher":"Molecular metabolism","date":"2026","tag":"Preclinical study","accessed_at":"2026-08-05T01:54:10.303Z","prev":"a767fd2c0ecd15f1406073dc1a969b13a3237c971f378da42aad18e8bc7fcb0c","hash":"a765e6ad75fa03829c75d78bec6cc921cb3415412f31455b1f6aef79d25c3f33"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41787737/","external_id":"41787737","pmid":"41787737","title":"Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials","quote":"Retatrutide demonstrated the greatest weight reduction versus placebo (MD -13.44 kg; 95% CI [-18.38, -8.51]), followed by survodutide (MD -10.74 kg; 95% CI [-15.68, -5.80]","summary":"Endocrinology, Diabetes & Metabolism 2026: a network comparison of the glucagon-receptor drugs. Retatrutide led on weight and on HbA1c, and was the only one of four whose HbA1c effect reached statistical significance.","author":"Abulehia A, Ayesh H et al.","publisher":"Endocrinology, diabetes & metabolism","date":"2026","tag":"Network meta-analysis","accessed_at":"2026-08-05T01:54:10.303Z","prev":"a765e6ad75fa03829c75d78bec6cc921cb3415412f31455b1f6aef79d25c3f33","hash":"74be946afbee8ee645a7f0e95059c9ee8ac7501ffc2a9658d868850854897acb"},{"id":"s13","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","external_id":"40741227","pmid":"40741227","title":"Triple Agonism Based Therapies for Obesity","quote":"In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤ 6.5%.","summary":"Current Cardiovascular Risk Reports 2025: the diabetes results, alongside improvements in blood pressure, lipids, waist circumference and an 82% reduction in liver fat.","author":"Goldney J, Hamza M et al.","publisher":"Current cardiovascular risk reports","date":"2025","tag":"Review","accessed_at":"2026-08-05T01:54:10.303Z","prev":"74be946afbee8ee645a7f0e95059c9ee8ac7501ffc2a9658d868850854897acb","hash":"cdb47984aca1cc23f8a7659ae840a2f68f096cd9dd1b65e82ea65f7a5dbabde6"},{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","external_id":"40609566","pmid":"40609566","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"Percent reduction from baseline in total fat mass was 4·9% (SE 1·4%) with retatrutide 0·5 mg, 15·2% (3·2%) with retatrutide 4 mg (pooled), 26·1% (2·5%) with retatrutide 8 mg (pooled), 23·2% (3·0%) with retatrutide 12 mg, 2·6% (1·6","summary":"Lancet Diabetes & Endocrinology 2025: body composition measured directly rather than inferred. Manufacturer-funded, and 85% of participants were White.","author":"Coskun T, Wu Q et al.","publisher":"The lancet. Diabetes & endocrinology","date":"2025","tag":"Randomised substudy","accessed_at":"2026-08-05T01:54:10.303Z","prev":"cdb47984aca1cc23f8a7659ae840a2f68f096cd9dd1b65e82ea65f7a5dbabde6","hash":"76dac7c5455e1d91a268ba6a445d0b2bf5b41e6e172c8a38098846f1b54fd980"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","external_id":"40609566","pmid":"40609566","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"The proportion of lean mass loss to weight loss was similar to other obesity treatments.","summary":"The same substudy on the standard objection to very effective weight drugs: more total weight comes off, and the share of it that is muscle is not disproportionate.","author":"Coskun T, Wu Q et al.","publisher":"The lancet. Diabetes & endocrinology","date":"2025","tag":"Randomised substudy","accessed_at":"2026-08-05T01:54:10.303Z","prev":"76dac7c5455e1d91a268ba6a445d0b2bf5b41e6e172c8a38098846f1b54fd980","hash":"5e728380c6628f75e916098b674f72427d32a5e6fb816d1e0b1f4f4a30d78321"},{"id":"s16","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41831086/","external_id":"41831086","pmid":"41831086","title":"Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes","quote":"An expanding pipeline of dual glucagon/GLP-1 and triple GIP/GLP-1/glucagon agonists such as retatrutide has shown marked reductions in liver fat and signals of MASH benefit.","summary":"Current Diabetes Reports 2026: fatty liver disease has only two specifically approved drugs, which is the context for how large the liver fat result is.","author":"Malandris K, Charalampidis K et al.","publisher":"Current diabetes reports","date":"2026","tag":"Review","accessed_at":"2026-08-05T01:54:10.303Z","prev":"5e728380c6628f75e916098b674f72427d32a5e6fb816d1e0b1f4f4a30d78321","hash":"9fe1f80a88af676131ba4635d1d6368a31fe06cabde3efa2a5b76cd2306ac028"},{"id":"s17","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42195239/","external_id":"42195239","pmid":"42195239","title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression","quote":"These therapies may also exert beneficial effects on fibrosis progression; however, the currently available evidence remains limited.","summary":"Medicina 2026: the distinction that decides whether this becomes a liver drug — reducing fat in the liver is not the same as changing the scarring that fat drives.","author":"Abenavoli L, Loricchio AG et al.","publisher":"Medicina (Kaunas, Lithuania)","date":"2026","tag":"Narrative review","accessed_at":"2026-08-05T01:54:10.303Z","prev":"9fe1f80a88af676131ba4635d1d6368a31fe06cabde3efa2a5b76cd2306ac028","hash":"8b06faef02e21781983a0089d6c4ba36864fb9cc0de7e735a607aa1a99777b24"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40916752/","external_id":"40916752","pmid":"40916752","title":"Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study","quote":"On average, people who experienced greater weight reduction also reported being less hungry and less likely to overeat.","summary":"Diabetes, Obesity & Metabolism 2025: the first study of appetite and eating behaviour on this drug. The people reporting the biggest hunger changes were the same people losing the most weight.","author":"Kanu C, Boye KS et al.","publisher":"Diabetes, obesity & metabolism","date":"2025","tag":"Substudy","accessed_at":"2026-08-05T01:54:10.303Z","prev":"8b06faef02e21781983a0089d6c4ba36864fb9cc0de7e735a607aa1a99777b24","hash":"9d9659b988d0f149cf0334855f280d596f2b07ab9094c61470dade787f98e93d"},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","external_id":"40741227","pmid":"40741227","title":"Triple Agonism Based Therapies for Obesity","quote":"Gastrointestinal symptoms were the most common side effects; no major safety concerns were observed.","summary":"The phase 2 safety picture. Phase 2 enrols hundreds of people for months — rare and long-term harms are not what it is built to detect.","author":"Goldney J, Hamza M et al.","publisher":"Current cardiovascular risk reports","date":"2025","tag":"Review","accessed_at":"2026-08-05T01:54:10.303Z","prev":"9d9659b988d0f149cf0334855f280d596f2b07ab9094c61470dade787f98e93d","hash":"9a4af7e86f4b1875439d2ff8ad4c9bb53736b26d80756f6e3b1501ab23696277"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40988099/","external_id":"40988099","pmid":"40988099","title":"Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","quote":"Pancreatic cancer and GLP-1 RA use showed no significant association (RR: 1.30, 95% CI 0.86-1.97).","summary":"Endocrinology, Diabetes & Metabolism 2025: a class-level finding for GLP-1 receptor agonists — slightly increased pancreatitis risk, no significant pancreatic cancer association. An inference for retatrutide from shared mechanism, not a measurement of it.","author":"Wen J, Nadora D et al.","publisher":"Endocrinology, diabetes & metabolism","date":"2025","tag":"Meta-analysis","accessed_at":"2026-08-05T01:54:10.303Z","prev":"9a4af7e86f4b1875439d2ff8ad4c9bb53736b26d80756f6e3b1501ab23696277","hash":"5ca283da647c1cc730630d2e374aadd73bde8f5fed21a6b7e7eaa2ba42688ee9"},{"id":"s21","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","external_id":"40741227","pmid":"40741227","title":"Triple Agonism Based Therapies for Obesity","quote":"A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D.","summary":"Where the drug actually is: phase 2 complete, phase 3 running, cardiovascular and kidney outcomes not yet reported.","author":"Goldney J, Hamza M et al.","publisher":"Current cardiovascular risk reports","date":"2025","tag":"Review","accessed_at":"2026-08-05T01:54:10.303Z","prev":"5ca283da647c1cc730630d2e374aadd73bde8f5fed21a6b7e7eaa2ba42688ee9","hash":"cd0cad1435cf84fad1e7fac4fb2f1f9f6e906fd55bd3bc629b2e9f7e6655015a"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545327/","external_id":"41545327","pmid":"41545327","title":"The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities","quote":"Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease.","summary":"Clinical Pharmacology in Drug Development 2026: a perspective calling the drug a watershed, written before any phase 3 result exists. Included as an example of the register these results attract.","author":"Ganamurali N, Sabarathinam S.","publisher":"Clinical pharmacology in drug development","date":"2026","tag":"Perspective","accessed_at":"2026-08-05T01:54:10.303Z","prev":"cd0cad1435cf84fad1e7fac4fb2f1f9f6e906fd55bd3bc629b2e9f7e6655015a","hash":"701b135b037d228e2b1825bb811eacfea9aac9936ab3b86f5127007bc4ad3409"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41297910/","external_id":"41297910","pmid":"41297910","title":"Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders","quote":"These agents offer broad clinical utility beyond glucose lowering by mimicking the pleiotropic hormonal responses observed after bariatric surgery.","summary":"Clinical and Molecular Hepatology 2026: why the effects are this large. These molecules copy the several-hormone response the body produces after bariatric surgery rather than amplifying one signal.","author":"Cho YK, Jung CH.","publisher":"Clinical and molecular hepatology","date":"2026","tag":"Review","accessed_at":"2026-08-05T01:54:10.303Z","prev":"701b135b037d228e2b1825bb811eacfea9aac9936ab3b86f5127007bc4ad3409","hash":"0d986402992fb62d477f25f9b6b7d6e3a4634c0581336bb174bc231f56fd551b"},{"id":"s24","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","external_id":"42250575","pmid":"42250575","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"490 (91%) participants completed the treatment period on study drug and 504 (94%) completed the study.","summary":"The same phase 3 trial's retention figures. For a drug whose main side effects are gastrointestinal, 91% completing on the study drug is itself a tolerability result.","author":"Bajaj HS, Welch M et al.","publisher":"Lancet (London, England)","date":"2026","tag":"Phase 3 trial","accessed_at":"2026-08-05T01:54:10.303Z","prev":"0d986402992fb62d477f25f9b6b7d6e3a4634c0581336bb174bc231f56fd551b","hash":"1ab5e0df5e49b2da3698bbc16b7c9ea5ae2f46b47ea53294e5c4acf46c88b54d"}]}